|Bid||5,039.21 x 100|
|Ask||5,460.00 x 100|
|Day's range||0.00 - 0.00|
|Beta (5Y monthly)||0.42|
|PE ratio (TTM)||14.21|
|Earnings date||18 Oct 2022 - 24 Oct 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Baird Senior Research Analyst Brian Skorney joins Yahoo Finance Live to discuss the breakthrough of Biogen's Alzheimer's drug, which is pushing the stock higher.
Biogen stock rips higher on a promising new drug. Here's what Wall Street is saying.
New clinical trial results are great, but this company's Alzheimer's disease program has deeply disappointed investors in the past.